Alseres Pharmaceuticals, Inc. (ALSE)
USD 0.01
(100.0%)
USD 0.01
(100.0%)
| Breakdown | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.68 Million | -952.44 Thousand | -2.48 Million | -2.95 Million | -8.06 Million | -14.98 Million |
| Net Income | -941.52 Thousand | -1.64 Million | - | 512.41 Thousand | -10.77 Million | -20.84 Million |
| Depreciation & Amortization | 1186.00 | 1289.00 | 40.75 Thousand | 58.59 Thousand | 72.37 Thousand | 52.95 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -1.29 Million | 691.73 Thousand | 852.45 Thousand | 934.18 Thousand | 454.82 Thousand | 3.41 Million |
| Other non-cash items | 546.25 Thousand | - | -3.37 Million | -4.45 Million | 2.18 Million | 2.39 Million |
| Investing Cash Flow | 884.35 Thousand | - | 301.38 Thousand | 35.01 Thousand | 76.47 Thousand | 1.12 Million |
| Investments in PPE | - | - | -2373.00 | - | - | -143.11 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | -258.00 | -2284.00 |
| Sales/Maturities of investments | 884.35 Thousand | - | - | 35.01 Thousand | 76.73 Thousand | 1.26 Million |
| Other Investing Activities | 884.35 Thousand | - | 303.76 Thousand | - | - | - |
| Financing Cash Flow | 900 Thousand | 833.13 Thousand | 2.22 Million | 2.69 Million | 8.22 Million | 11 Million |
| Debt repayment | -725 Thousand | - | -1000.00 | -602.7 Thousand | -25.18 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -1866.00 | -18.25 Thousand | -8100.00 | - | - |
| Common Stock Issuance | - | - | - | - | 2 Million | 1 Million |
| Other Financing Activities | 900 Thousand | 835 Thousand | 2.24 Million | 3.31 Million | 6.25 Million | 10 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -1.29 Million | 691.73 Thousand | 852.45 Thousand | - | - | - |
| Cash at beginning of period | 16.52 Thousand | 135.84 Thousand | 98.51 Thousand | 314.96 Thousand | 73.97 Thousand | 2.93 Million |
| Cash at end of period | 113.95 Thousand | 16.52 Thousand | 135.84 Thousand | 98.51 Thousand | 314.96 Thousand | 73.97 Thousand |
| Capital Expenditure | - | - | -2373.00 | - | - | -143.11 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 97.43 Thousand | -119.31 Thousand | 37.32 Thousand | -216.45 Thousand | 240.99 Thousand | -2.85 Million |
| Free Cash Flow | -1.68 Million | -952.44 Thousand | -2.48 Million | -2.95 Million | -8.06 Million | -15.12 Million |
| Breakdown | 2014 Q2 | 2014 Q1 | 2013 FY | 2013 Q4 | 2013 Q3 | 2013 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -321 Thousand | -332.01 Thousand | -941.52 Thousand | 239.04 Thousand | -362.66 Thousand | -520.05 Thousand |
| Depreciation & Amortization | - | - | 1186.00 | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 48.93 Thousand | -53.43 Thousand | -1.29 Million | -944.19 Thousand | 61.87 Thousand | 164.17 Thousand |
| Other non-cash items | 43.92 Thousand | -33.05 Thousand | 546.25 Thousand | 319.17 Thousand | -62.24 Thousand | 56.31 Thousand |
| Investing Cash Flow | - | - | 884.35 Thousand | 22.74 Thousand | - | 134.68 Thousand |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | 884.35 Thousand | 22.74 Thousand | - | 134.68 Thousand |
| Other Investing Activities | - | - | 884.35 Thousand | 22.74 Thousand | - | 134.68 Thousand |
| Financing Cash Flow | 225 Thousand | 365 Thousand | 900 Thousand | 450 Thousand | 300 Thousand | 100 Thousand |
| Debt repayment | -225 Thousand | -365 Thousand | -725 Thousand | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | 900 Thousand | 450 Thousand | 300 Thousand | 100 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 62.35 Thousand | -14.62 Thousand | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -13.41 Thousand | -38.81 Thousand | -1.29 Million | -944.19 Thousand | 61.87 Thousand | 164.17 Thousand |
| Cash at beginning of period | 93.5 Thousand | 113.95 Thousand | 16.52 Thousand | 27.19 Thousand | 27.98 Thousand | 92.86 Thousand |
| Cash at end of period | 46.44 Thousand | 93.5 Thousand | 113.95 Thousand | 113.95 Thousand | 27.19 Thousand | 27.98 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -47.06 Thousand | -20.45 Thousand | 97.43 Thousand | 86.76 Thousand | -790.00 | -64.87 Thousand |
| Free Cash Flow | -272.06 Thousand | -385.45 Thousand | -1.68 Million | -385.97 Thousand | -300.79 Thousand | -299.56 Thousand |
OGC
ACRE
BIO
353810
BAZA3
LCTX